Early-Onset Colorectal Adenocarcinoma in the IDEA Database: Treatment Adherence, Toxicities, and Outcomes With 3 and 6 Months of Adjuvant Fluoropyrimidine and Oxaliplatin
暂无分享,去创建一个
R. Labianca | J. Meyerhardt | E. Oki | V. Georgoulias | F. Lordick | A. Shields | I. Boukovinas | I. Ben-Aharon | D. Vernerey | J. Taieb | Q. Shi | T. Yoshino | S. Lonardi | T. André | A. Sobrero | E. Smyth | M. Moehler | T. Iveson | M. Saunders | I. Souglakos | A. Harkin | J. Meyers | E. Fontana | A. Giraut
[1] N. Wolmark,et al. Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] S. Ogino,et al. Rising incidence of early-onset colorectal cancer — a call to action , 2020, Nature Reviews Clinical Oncology.
[3] E. Van Cutsem,et al. Clinicopathological and molecular biological characteristics of early-onset stage II/III colorectal adenocarcinoma: An analysis of 25 studies with 47,184 patients (pts) in the adjuvant colon cancer end points (ACCENT) database. , 2020 .
[4] A. Jemal,et al. Global patterns and trends in colorectal cancer incidence in young adults , 2019, Gut.
[5] G. Frampton,et al. Comprehensive Genomic Landscapes in Early and Later Onset Colorectal Cancer , 2019, Clinical Cancer Research.
[6] R. Labianca,et al. Duration of Adjuvant Chemotherapy for Stage III Colon Cancer , 2018, The New England journal of medicine.
[7] A. Jemal,et al. Colorectal Cancer Mortality Rates in Adults Aged 20 to 54 Years in the United States, 1970-2014 , 2017, JAMA.
[8] Hong Zhang,et al. The prognostic factors and multiple biomarkers in young patients with colorectal cancer , 2015, Scientific Reports.
[9] J. Skibber,et al. Overtreatment of young adults with colon cancer: more intense treatments with unmatched survival gains. , 2015, JAMA surgery.
[10] P. Butow,et al. Symptom clusters in patients with advanced cancer: a systematic review of observational studies. , 2014, Journal of pain and symptom management.
[11] D. Ahnen,et al. The increasing incidence of young-onset colorectal cancer: a call to action. , 2014, Mayo Clinic proceedings.
[12] P. Gibbs,et al. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer , 2011, Cancer.
[13] M. Aapro,et al. Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy , 2010, Supportive Care in Cancer.